Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1927 1
1930 1
1938 1
1939 1
1941 2
1943 1
1945 5
1946 19
1947 32
1948 33
1949 48
1950 42
1951 51
1952 46
1953 53
1954 45
1955 56
1956 63
1957 60
1958 74
1959 69
1960 75
1961 78
1962 72
1963 76
1964 118
1965 112
1966 103
1967 148
1968 188
1969 206
1970 267
1971 316
1972 336
1973 346
1974 335
1975 313
1976 414
1977 371
1978 355
1979 379
1980 441
1981 435
1982 466
1983 530
1984 511
1985 550
1986 538
1987 516
1988 541
1989 564
1990 512
1991 554
1992 580
1993 532
1994 597
1995 658
1996 660
1997 683
1998 800
1999 793
2000 848
2001 964
2002 1005
2003 1143
2004 1209
2005 1314
2006 1385
2007 1599
2008 1615
2009 1844
2010 2009
2011 2125
2012 2214
2013 2455
2014 2534
2015 2538
2016 2720
2017 2727
2018 2730
2019 2975
2020 3332
2021 3462
2022 9
Text availability
Article attribute
Article type
Publication date

Search Results

56,983 results
Results by year
Filters applied: . Clear all
Page 1
Efficacy of JAK inhibitors in Crohn's Disease.
Rogler G. Rogler G. J Crohns Colitis. 2020 Aug 1;14(Supplement_2):S746-S754. doi: 10.1093/ecco-jcc/jjz186. J Crohns Colitis. 2020. PMID: 31781755 Free PMC article. Review.
Inhibition of Janus kinases [JAKs] in Crohn's disease [CD] patients has shown conflicting results in clinical trials. ...
Inhibition of Janus kinases [JAKs] in Crohn's disease [CD] patients has shown conflicting results in clinical trials. ...
An overview of cannabis based treatment in Crohn's disease.
Naftali T. Naftali T. Expert Rev Gastroenterol Hepatol. 2020 Apr;14(4):253-257. doi: 10.1080/17474124.2020.1740590. Epub 2020 Mar 12. Expert Rev Gastroenterol Hepatol. 2020. PMID: 32149543 Review.
Unfortunately, so far there are only three small placebo controlled study regarding the use of cannabis in active Crohns disease, combining altogether 93 subjects. Two of the studies showed significant clinical improvement but no improvement in markers of inflammation.Expe …
Unfortunately, so far there are only three small placebo controlled study regarding the use of cannabis in active Crohns disease, com …
Role of Epithelial-to-Mesenchymal Transition in Inflammatory Bowel Disease.
Lovisa S, Genovese G, Danese S. Lovisa S, et al. J Crohns Colitis. 2019 Apr 26;13(5):659-668. doi: 10.1093/ecco-jcc/jjy201. J Crohns Colitis. 2019. PMID: 30520951 Review.
Intestinal fibrosis is an inevitable complication in patients with inflammatory bowel disease [IBD], occurring in its two major clinical manifestations: ulcerative colitis and Crohn's disease. Fibrosis represents the final outcome of the host reaction to persistent …
Intestinal fibrosis is an inevitable complication in patients with inflammatory bowel disease [IBD], occurring in its two major clinical man …
IBD: In Food We Trust.
Marion-Letellier R, Savoye G, Ghosh S. Marion-Letellier R, et al. J Crohns Colitis. 2016 Nov;10(11):1351-1361. doi: 10.1093/ecco-jcc/jjw106. Epub 2016 May 17. J Crohns Colitis. 2016. PMID: 27194533 Review.
However, scientific evidence to support dietary advice is currently lacking, and dietary counselling for IBD patients is often limited in clinical practice to the improvement of nutrient intake. This review aimed to focus on both patient's beliefs about and molecular mecha …
However, scientific evidence to support dietary advice is currently lacking, and dietary counselling for IBD patients is often limited in cl …
Medical management of fistulising Crohn's disease.
Grimstad T, Carlsen A, Karlsen LN. Grimstad T, et al. Tidsskr Nor Laegeforen. 2019 Jan 9;139(1). doi: 10.4045/tidsskr.17.1055. Print 2019 Jan 15. Tidsskr Nor Laegeforen. 2019. PMID: 30644688 Free article. Review. English, Norwegian. No abstract available.
Are Patients with Inflammatory Bowel Disease at Increased Risk for Covid-19 Infection?
Monteleone G, Ardizzone S. Monteleone G, et al. J Crohns Colitis. 2020 Sep 16;14(9):1334-1336. doi: 10.1093/ecco-jcc/jjaa061. J Crohns Colitis. 2020. PMID: 32215548 Free PMC article.
Crohn's disease [CD] and ulcerative colitis [UC], the main inflammatory bowel diseases [IBD] in humans, are chronic, immune-inflammatory diseases, the pathogenesis of which suggests a complex interaction between environmental factors and genetic susceptibility. ...
Crohn's disease [CD] and ulcerative colitis [UC], the main inflammatory bowel diseases [IBD] in humans, are chronic, immune-in
European Crohn's and Colitis Organisation Topical Review on IBD in the Elderly.
Sturm A, Maaser C, Mendall M, Karagiannis D, Karatzas P, Ipenburg N, Sebastian S, Rizzello F, Limdi J, Katsanos K, Schmidt C, Jeuring S, Colombo F, Gionchetti P. Sturm A, et al. J Crohns Colitis. 2017 Mar 1;11(3):263-273. doi: 10.1093/ecco-jcc/jjw188. Epub 2016 Oct 20. J Crohns Colitis. 2017. PMID: 27797918 Free article.
This ECCO topical review of the European Crohn's and Colitis Organisation [ECCO] focuses on the epidemiology, pathophysiology, diagnosis, management and outcome of the two most common forms of inflammatory bowel disease, Crohn's disease and ulcerative …
This ECCO topical review of the European Crohn's and Colitis Organisation [ECCO] focuses on the epidemiology, pathophysiology, …
An Overview of the Mechanism of Action of the Monoclonal Antibody Vedolizumab.
Wyant T, Fedyk E, Abhyankar B. Wyant T, et al. J Crohns Colitis. 2016 Dec;10(12):1437-1444. doi: 10.1093/ecco-jcc/jjw092. Epub 2016 Jun 1. J Crohns Colitis. 2016. PMID: 27252400 Review.
Vedolizumab is a novel therapeutic monoclonal antibody recently approved for the treatment of moderately to severely active ulcerative colitis and Crohn's disease in adults who have failed at least one conventional therapy. ...
Vedolizumab is a novel therapeutic monoclonal antibody recently approved for the treatment of moderately to severely active ulcerative colit …
56,983 results
You have reached the last available page of results. Please see the User Guide for more information.